Ś

SIGNATURE

Approved for use through 10/31/2002 OMB 0651-0632

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCY
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

O LUCII ITA	Attorney Docket No	PF105P1D2				
UTILITY DATENT ADDITION	First Inventor	Kirkness et al.				
PATENT APPLICATION TRANSMITTAL	Title Human Haemopoietic Maturation Factor					
(Only for new nonprovisional applications under 37 CFR ' 1 53(b))	Express Mail Label No. N/A					
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Bo	sistant Commissioner for Patents x Patent Application ashington, DC 20231				
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	Program (Appendix)	in duplicate, large table or Computer				
2. Applicant claims small entity status.  See 37 CFR 1.27.	<ul> <li>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</li> <li>a. Computer Readable Form (CRF)</li> </ul>					
3. Specification [Total Pages: 37]  (preferred arrangement set forth below)  - Descriptive title of the Invention  - Cross Reference to Related Applications  - Statement Regarding Fed sponsored R & D  - Reference to sequence listing, a table,	b. Specification Sequence Listing on:  iCD-ROM or CD-R (2 copies); or  ii paper [Total Pages : 5]  cStatements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS					
or a computer program listing appendix - Background of the Invention						
- Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	10. ☐ 37 CFR 3.73(b) St 11. ☐ English Translatio	s (cover sheet & document(s)) tatement				
4. \( \text{Drawing(s) (35 U.S.C. 113)} \) [Total Sheets \( \frac{8}{2} \) ]	Copies of Citation					
5. 🛮 Oath or Declaration [Total Pages 2]	<ul><li>13. ☐ Preliminary Amen</li><li>14. ☒ Return Receipt Po</li></ul>					
a. ☐ Newly executed (original or copy) b. ☑ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' ' 1.63(d)(2) and 1.33(b).  6. ☑ Application Data Sheet. See 37 CFR 1.76. [4 Pages]	(should be specifically item  15. Certified Copy of  (if foreign priority is claims	nzed) Priority Document(s)  ed) Powers of Attorney from priority				
17. If a CONTINUING APPLICATION, check appropriate box, an	d supply the requisite information	n below and in a preliminary amendment,				
or in an Application Data Sheet under 37 CFR 1.76:						
Continuation Divisional Continuation-in-Pa	art (CIP) of prior application	n No: 09/333,033. filed June 15, 1999				
Prior application information: Examiner: Kemmerer, E. Group/Art Unit: 1646						
For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted						
18. CORRESPONDENCE ADDRESS						
Customer Number of But Code Laber	Customer Number or Bar Code Label 22195 or Correspondence address below					
NAME						
ADDRESS		Tan con T				
CITY STATE		ZIP CODE				
COUNTRY TELEPHONE	Production 3	FAX				
NAME (Print/Type) Mark J. Hyman	Kegistration I	No. (Attorney/Agent) 46,789				
SIGNATURE		Date December 7, 2001				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Total amount of payment

\$848.00

Complete if Known				
Application Number	Unassigned			
Filing Date	Herewith			
First Named Inventor	Kirkness et al.			
Examiner Name	Unassigned			
Group Art Unit	Unassigned			
Attorney Docket Number	PF105P1D2			

METHOD OF PAYMENT				FEE CA	ALCULATION (continued)	
1.  The Commissioner is hereby authorized to charge	3.			FEES		
indicated fees and credit any overpayments to:	1	Large		Small		i
Deposit Account Number 08-3425	Fee	Entity Fee	Fee	Entity Fee		l
Deposit Account Name Human Genome Sciences, Inc.	Cod		Code	(\$)	Fee Description	Fee Paid
Charge Any Additional Fee Required	10	5 130	205	65	Surcharge - late filing fee or oath	L
Under 37 CFR §§ 1 16 and 1.17	12	7 50	227	25	Surcharge - late provisional filing fee or cover sheet	1
Applicant claims small entity status.	13	9 130	139	130	Non-English specification	
See 37 CFR 1 27		7 2,520	147	2,520	For filing a request for ex parte reexammation	
Total Control		2 920°	112	920*	Requesting publication of SIR prior to Examiner action	
2 Payment Enclosed: Check Credit Card Money Order Other		3 1,840°	113	1,840*	Requesting publication of SIR after Examiner action	
FEE CALCULATION	7 11	5 110	215	55	Extension for reply within first month	
1.=BASIC FILING FEE	11	6 400	216	200	Extension for reply within second month	
Large Entity Small Entity	ti	7 920	217	460	Extension for reply within third month	
Fee Fee Fee Fee Description Fee Pa	d 11	8 1,440	218	720	Extension for reply within fourth month	
Code         (\$)         Code         (\$)           F101         740         201         370         Utility filing fee         \$740.	00 12	8 1,960	228	980	Extension for reply within fifth month	
106 330 206 165 Design filing fee	11		219	160	Notice of appeal	
107 510 207 255 Plant filing fee	12		220	160	Filing a brief in support of an appeal	
108 740 208 370 Reissue filing fee	12	1 280	221	140	Request for oral hearing	
114 160 214 80 Provisional filing fee	13	8 1,510	138	1,510	Petition to institute a public use hearing	
SUBTOTAL (1) \$740.0	0 14	0 110	240	55	Petition to revive - unavoidable	
EEXTRA CLAIM FEES	14	1,280	241	640	Petition to revive - unintentional	
Extra Fee from Fee Pa Claims below	d 14	1,280	242	640	Utility issue fee (or reissue)	
Total Claims 26 -20** 6 \$18.00 \$108.	00 14	3 460	243	230	Design issue fee	
Independent 3 -3** 0 \$84.00 \$0.	00 14	4 620	244	310	Plant issue fee	
Multiple Dependent \$280.00 \$108.	_		122	130	Petitions to the Commissioner	\
	12		123	50	Processing fee under 37 CFR 1.17(q)	ļ
	12	26 180	126	180	Submission of Information Disclosure Statement Recording each patent assignment per	
	58	3] 40	581	40	property (times number of properties)	
Large Entity Small Entity	14	740	246	370	Filing a submission after final rejection (37 CFR § 1 129(a))	
Fee Fee Fee Fee Code (S) Code (\$)	14	19 740	249	370	For each additional invention to be examined (37 CFR § 1 129(b))	)
103 18 203 9 Claims in excess of 20	17	79 740	279	370	Request for Continued Examination (RCE)	
102 84 202 42 Independent claims in excess of 3	16	900	169	900	Request for expedited examination of a design application	
104 280 204 140 Multiple dependent claim, if not pa	ıd 14	15 100	145	100	Certificate of correction	
108 84 209 42 Reissue independent claims over	- 1	110	248	55	Statutory disclaimer	
original patent 110 18 210 9 Reissue claims in excess of 20	1				•	
and over original patent	56	51 3	561	3	Printed copy of patent, regular service (8 copies)	
	Oth	er fee (specify	i)·			
SUBTOTAL (2) \$108.0	0 Oth	er fee (specify	<i>i</i> ).			
or number previously paid, if greater; For Reissues, see above	·Re	educed by Bas	ic Filing	Fee Paid	SUBTOTAL (3)	\$0.00

Submitted By		Complete (if applicable)
Name (Print/Type) Mark J. Hyman	Registration No.: 46,789	Telephone: (240) 314-1224
Signature: Mall		Date: December 7, 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kirkness et al. Atty. Docket No.: PF105P1D2

Application Number: Unassigned Group Art Unit: Unassigned

Filed: Herewith Examiner: Unassigned

Title: Human Haemopoietic Maturation Factor

## STATEMENT UNDER 37 C.F.R. § 1.821

Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper) Sequence Listing submitted herewith.

Respectfully submitted,

Date: December 7, 2001

Mark J. Hyman Attorney for Applicants Reg. No. 46,789

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (240) 314-1224

KKH/MJH/ba